WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has completed its application for U.S. approval of QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations, moving the Wayne-based biotechnology company toward a potential first-half 2027 commercial launch if the therapy clears regulatory review.
The New Drug Application seeks approval for a rare genetic disease affecting an estimated more than 30,000 pediatric and adult patients in the U.S. There are currently no FDA-approved therapies for microcystic lymphatic malformations, according to Palvella.
The Food and Drug Administration will determine within 60 days whether the application is sufficiently complete for filing and whether to grant Priority Review. A Priority Review designation would carry a six-month review goal.
QTORIN rapamycin previously received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. The FDA also recently permitted Palvella to submit its application on a rolling basis.
The filing is supported by the company’s Phase 3 SELVA trial, which met its primary endpoint, a prespecified key secondary endpoint and four additional secondary efficacy endpoints. All six efficacy endpoints reached statistical significance at p<0.001, Palvella reported.
Among trial participants ages 6 and older who completed the efficacy evaluation period, 86% were rated “Much Improved” or “Very Much Improved” at Week 24 using the Microcystic Lymphatic Malformation Investigator Global Assessment, the study’s primary endpoint.
Palvella reported no drug-related serious adverse events in the trial. Systemic rapamycin concentrations remained below 2 ng/mL at all measured time points for all participants.
The application also incorporates Phase 2 results that supported the FDA’s Breakthrough Therapy designation, along with published literature and other evidence concerning off-label use of rapamycin for microcystic lymphatic malformations.
Palvella filed under the FDA’s 505(b)(2) pathway, which permits an applicant to rely partly on previous findings of safety and effectiveness and other existing data rather than generating all supporting information independently.
“Completing the submission of our NDA brings us one step closer to our goal of delivering the first FDA-approved therapy for patients living with microcystic LMs,” Chief Executive Officer Wes Kaupinen said.
With the regulatory application completed, Palvella is preparing for a possible U.S. launch in the first half of 2027. The company has assembled commercial leadership, deployed a field-based medical science liaison team across the country and established a patient-services organization.
QTORIN rapamycin remains investigational and has not been approved by the FDA or another regulatory agency for any indication.
Palvella is also developing QTORIN rapamycin for cutaneous venous malformations and clinically significant angiokeratomas. A second candidate, QTORIN pitavastatin, is under development for disseminated superficial actinic porokeratosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.